Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulability and thrombosis

R L Bick1

  • 1Department of Oncology and Hematology, Presbyterian Hospital of Dallas, Texas.

The Medical Clinics of North America
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Identifying common hereditary and acquired blood protein defects, such as antithrombin deficiency and anticardiolipin antibodies, is crucial for diagnosing unexplained thrombosis. Further investigation into rarer defects can aid in patient therapy and family screening.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contaminants in heparins continue to be unfolded.

International angiology : a journal of the International Union of Angiology·2008
Same author

The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.

Clinical hemorheology and microcirculation·2007
Same author

Antiphospholipid thrombosis syndromes.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2001
Same author

Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2001
Same author

Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism.

Drugs·2000
Same author

An update on heparins at the beginning of the new millennium.

Seminars in thrombosis and hemostasis·2000
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Hematology
  • Thrombosis Research
  • Genetic Disorders

Background:

  • Thrombosis is often linked to hereditary and acquired blood protein defects.
  • Common hereditary defects include antithrombin, protein C, and protein S deficiencies.
  • Acquired defects frequently involve anticardiolipin antibodies and lupus anticoagulant.

Purpose of the Study:

  • To highlight the importance of identifying specific blood protein defects in patients with unexplained thrombosis.
  • To guide the diagnostic approach by prioritizing common defects before rarer ones.
  • To underscore the therapeutic and familial implications of diagnosing these defects.

Main Methods:

  • Review of existing literature on hereditary and acquired thrombotic defects.
  • Emphasis on the diagnostic hierarchy of protein defects.

Related Experiment Videos

  • Discussion of implications for patient management and family screening.

    • Main Results:

    • Common hereditary defects: antithrombin, protein C, and protein S deficiencies.
    • Common acquired defects: anticardiolipin antibodies and lupus anticoagulant.
    • Rarer defects to consider: HC-II, plasminogen or t-PA deficiency, dysfibrinogenemia, elevated PAI-1.

    Conclusions:

    • Prioritizing the investigation of common hereditary and acquired defects is essential for unexplained thrombosis.
    • Identifying these defects impacts individual therapy and enables proactive family studies.
    • Further research may reveal additional common defects, such as those related to activated protein C cofactor and PAI-1.